浙江康恩贝制药股份有限公司 关于持股 5%以上股东及其一致行动人权益变动的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 以上股东及其一致行动人康恩贝集团有限公司（以下简称"康恩贝集团"）、胡季强先生、浙江 元中和生物产业发展有限公司（以下简称"元中和生物产业公司"）中的元中和生物产业公司通 过上海证券交易所以集中竞价交易方式减持其所持本公司股份，不触及要约收购。 股，占本公司现总股本 2,523,710,972 股（按 2025 年 8 月 4 日公司总股本计，下同）的比例 由 0.228% 减 少 至 0% ； 上 述 持 股 5%以 上 股 东 及 其 一 致 行 动 人 合 计 持 有 本 公 司 股 份 数 量 由 发生变化。 强先生、元中和生物产业公司中的元中和生物产业公司出具的《告知函》，自 2025 年 7 月 24 日至 2025 年 8 月 4 日，元中和生物产业公司通过上海证券交易所以集中 竞价交易方式将其所持本公司股份 5,759,063 股减持完毕，减持股数占公司现总股 ...

重要内容提示： 1、本次权益变动为浙江康恩贝制药股份有限公司（以下简称"公司""本公司"）持股 5% 以上股东及其一致行动人康恩贝集团有限公司（以下简称"康恩贝集团"）、胡季强先生、浙江 元中和生物产业发展有限公司（以下简称"元中和生物产业公司"）中的元中和生物产业公司通 过上海证券交易所以集中竞价交易方式减持其所持本公司股份，不触及要约收购。 证券代码：600572 证券简称：康恩贝 公告编号：临 2025-039 浙江康恩贝制药股份有限公司 关于持股 5%以上股东及其一致行动人权益变动的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 2、本次权益变动后，元中和生物产业公司持有本公司股份数量由 5,759,063 股减少至 0 股，占本公司现总股本 2,523,710,972 股（按 2025 年 8 月 4 日公司总股本计，下同）的比例 由 0.228%减少至 0%；上述持股 5%以上股东及其一致行动人合计持有本公司股份数量由 362,769,319 股减少至 357,010,256 股，占本公司现总股本比例 ...

Group 1 - The core point of the article is that Kang En Bei (600572.SH) announced a significant share reduction by a major shareholder, which may impact the company's stock performance [1] - From July 24, 2025, to August 4, 2025, Yuan Zhonghe Biological Industry Company completely reduced its holdings by 5.7591 million shares [1] - The reduced shares accounted for 0.228% of the company's total share capital [1]

Core Viewpoint - Zhejiang Kangnbei Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Tranexamic Acid Tablets (0.25g), which is expected to positively impact the company's performance [1][5]. Group 1: Drug Registration Details - The drug name is Tranexamic Acid Tablets, in tablet form, with a specification of 0.25g, classified as a Class 4 chemical drug [1]. - The registration certificate was issued under the approval number H20255025, confirming that the product meets the registration requirements [1][2]. Group 2: R&D and Market Context - The original manufacturer of Tranexamic Acid Tablets is Daiichi Sankyo Co., Ltd., which has both 0.25g and 0.5g specifications approved in Japan, with the 0.5g version already available in China [2]. - The drug is primarily used for various bleeding conditions caused by excessive fibrinolysis [2]. - As of now, approximately 6.27 million RMB has been invested in the research and development of this drug by Hangzhou Kangnbei [3]. - There are a total of 12 approved drug registration numbers for Tranexamic Acid Tablets in China, with 4 having passed or been deemed to have passed the consistency evaluation [4]. - The overall sales amount for Tranexamic Acid Tablets in the domestic retail and medical terminal market is projected to be 263 million RMB in 2024, reflecting a year-on-year growth of 12.24% [4]. Group 3: Impact on the Company - The approval of Tranexamic Acid Tablets as a Class 4 chemical drug indicates that it is considered to have passed the consistency evaluation for generic drugs, which is expected to have a positive impact on the company's performance [5]. - The company emphasizes the importance of drug research and development, maintaining strict quality and safety controls throughout the drug development, production, and sales processes [5].

Core Viewpoint - Kang En Bei's stock price experienced a decline of 1.06% on July 31, closing at 4.65 yuan, with a trading volume of 367,000 hands and a transaction amount of 171 million yuan [1] Company Overview - Kang En Bei operates in the pharmaceutical manufacturing industry, specifically within the traditional Chinese medicine sector, focusing on drug research, production, and sales [1] - The company's product range includes traditional Chinese medicine preparations, chemical raw materials and preparations, and biological products, indicating a comprehensive pharmaceutical industry chain [1] Recent Developments - On July 31, Kang En Bei announced that its wholly-owned subsidiary, Hangzhou Kang En Bei Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the drug registration certificate of Aminocaproic Acid Tablets, which are used to treat various bleeding symptoms caused by hyperfibrinolysis [1] - The research and development investment for this drug was approximately 6.27 million yuan, and it is considered to have passed the consistency evaluation for generic drugs [1] Market Activity - On the same day, the main funds for Kang En Bei saw a net outflow of 1.6435 million yuan, accounting for 0.01% of the circulating market value [1]

证券日报网讯7月31日晚间，康恩贝（600572）发布公告称，近日，公司全资子公司杭州康恩贝制药有 限公司收到国家药品监督管理局核准签发的规格为0.25g的氨甲环酸片《药品注册证书》。 ...

Group 1 - The core point of the article is that Kang En Bei Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for its 0.25g tranexamic acid tablets [2] - Kang En Bei's revenue composition for the year 2024 is as follows: manufacturing (pharmaceutical industry) accounts for 86.86%, commercial sales for 11.77%, and other businesses for 1.37% [2]

一、药品注册证书的主要内容 药品名称：氨甲环酸片 剂型：片剂 证券简称：康恩贝 证券代码：600572 编号：2025-038 浙江康恩贝制药股份有限公司 关于子公司氨甲环酸片获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其 内容的真实性、准确性和完整性承担法律责任。 近日，浙江康恩贝制药股份有限公司（以下简称"公司""本公司"）全资子公司杭 州康恩贝制药有限公司（以下简称"杭州康恩贝"）收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的规格为 0.25g 的氨甲环酸片《药品注册证书》，现将相关情 况公告如下： 规格：0.25g 注册分类：化学药品 4 类 上市许可持有人：杭州康恩贝 批准文号：国药准字 H20255025 证书编号：2025S02376 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。 二、该药品研发情况 氨甲环酸片的原研厂家为日本第一三共株式会社，其在日本获批上市的氨甲环酸片有 0.25g 规格和 0.5g 规格，其中 0.5g 规格在中国获批上市 ...

Core Viewpoint - Kangnibei (600572.SH) has received approval from the National Medical Products Administration for its subsidiary Hangzhou Kangnibei Pharmaceutical Co., Ltd. to market a 0.25g specification of Tranexamic Acid Tablets [1] Group 1 - The original manufacturer of Tranexamic Acid Tablets is Daiichi Sankyo Co., Ltd. from Japan, which has approved both 0.25g and 0.5g specifications in Japan, with the 0.5g specification already approved for sale in China [1] - Tranexamic Acid Tablets are primarily used for treating various bleeding conditions caused by acute or chronic, localized or systemic primary fibrinolysis, as well as secondary hyperfibrinolytic states due to disseminated intravascular coagulation [1]

氨甲环酸片的原研厂家为日本第一三共株式会社，其在日本获批上市的氨甲环酸片有0.25g规格和0.5g规 格，其中0.5g规格在中国获批上市。氨甲环酸片主要用于急性或慢性、局限性或全身性原发性纤维蛋白 溶解亢进所致的各种出血;弥散性血管内凝血所致的继发性高纤溶状态。 智通财经APP讯，康恩贝(600572.SH)发布公告，近日，公司全资子公司杭州康恩贝制药有限公司("杭州 康恩贝")收到国家药品监督管理局(以下简称"国家药监局")核准签发的规格为0.25g的氨甲环酸片《药品 注册证书》。 ...